A South Korean company is currently investing in the development of a messenger RNA (mRNA) vaccine. The principle is to inject COVID-19 mRNA into the human body to produce antibodies. The firm owns the technology of manufacturing a material that allows it to enter cells.
This cell membrane-like substance is essential for designing serum because mRNA, which is easily degraded, requires protection to be safely absorbed by the body.
The development of mRNA-based vaccines is faster than other methods because it is sufficient to obtain the mRNA inside the transmitter. American biotechnology companies Moderna and Pfizer use this process.
The technology in question is essential for the development of mRNA vaccines. That is why the Ministry of Health, the Korean Association of Pharmaceutical and Biopharmaceutical Manufacturers (KBMMA) and three companies have set up a consortium to collaborate in this matter.
An approach that aims to ensure the nation’s vaccine sovereignty in the Morning Clear to better combat viral pandemics. The group plans to develop the serum “Made in Korea” by next year and to produce 1 billion doses each year from 2023. The government aims to achieve self-sufficiency in vaccines as well as make every effort to develop a base. their exports.